医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PARIS

EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced that Niigata Spine Center is the first center in Japan to install the EOS system. The Company obtained last month regulatory approval to commercialize EOS in Japan, the world’s second largest medical imaging market.

Niigata Spine Surgery Center is specialized in all spinal conditions and treatments for adult and children and has a strong clinical research activity, with more than 150 scientific papers presented in the last five years at Japanese or international meetings.

Professor Hasegawa, head of the center, said, “I am very happy that our hospital is the first in Japan to be equipped with EOS. I have followed the progress of this technology and its remarkable adoption worldwide, from which I received excellent feedback. I am confident that EOS will quickly be successful in Japan and look forward to use it now for my patients.”

Marie Meynadier, CEO of EOS imaging, said, “We are pleased that the unique benefits of the EOS system will now be available to patients in Japan, the second largest medical imaging market after the United States. The installation at Niigata Spine Center approximately one month following regulatory approval demonstrates the strong interest in the EOS system in Japan and the positive results from our market development efforts with our local distribution partner. We look forward to continue expanding adoption of the EOS system in Japan, which is a key component of our strategy in the Asia-Pacific region.”

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit www.eos-imaging.com.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 70 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of €9.42 million and employs 70 people including an R&D team of 25 engineers. The Group is based in Paris and holds three subsidiaries in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore.

EOS imaging is listed on Compartment C of the Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: Annual results 2013 on January 22, 2014 (after market).